# A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

> **NCT03895372** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 179 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** PF-06826647 or Placebo
- **DRUG:** PF-06826647

## Key facts

- **NCT ID:** NCT03895372
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-11-26
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895372, "A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03895372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*